Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

SCYNEXIS, Inc. (SCYX) vs TherapeuticsMD, Inc. (TXMD)

SCYNEXIS, Inc. and TherapeuticsMD, Inc. are both Drug Manufacturers Specialty & Generic companies. SCYNEXIS, Inc. is the larger, with a market value of $45.0M against $24.7M — 1.8× the size. SCYNEXIS, Inc. grew revenue faster over the last twelve months: 682.5% against 27.8%. TherapeuticsMD, Inc. has the higher net margin (−6.64% vs −49.7%) and the higher return on invested capital (−13.8% vs −110.7%). Across the 16 metrics below, TherapeuticsMD, Inc. leads on 9 and SCYNEXIS, Inc. on 7.

Valuation

Metric SCYX TXMD Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 2.52 7.26 2.25
P/B 0.78 0.87 1.90
Price to free cash flow n/m 8.72 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 1.15 6.95 2.56
Earnings yield (47.61%) (1.14%) (2.99%)
Free cash flow yield (25.67%) 11.47% 0.00%

Profitability

Metric SCYX TXMD Drug Manufacturers Specialty & Generic median
Gross margin 100.00% 100.00% 53.94%
Operating margin (109.90%) (120.89%) 0.00%
Net margin (49.74%) (6.64%) 0.00%
Free cash flow margin (64.67%) 94.71% 0.00%
Return on equity (18.38%) (0.80%) (0.40%)
Return on assets (15.09%) (0.57%) (3.32%)
Return on invested capital (110.72%) (13.77%) 0.00%

Growth

Metric SCYX TXMD Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 682.47% 27.78% 10.01%
EPS growth (last fiscal year) 61.36% 73.68% —
Revenue growth, 5-year CAGR 179.40% (45.84%) 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric SCYX TXMD Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.00 0.05
Current ratio 9.65 3.22 2.31
Net debt to EBITDA 2.54 2.34 0.85

Dividend

Metric SCYX TXMD Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric SCYX TXMD Drug Manufacturers Specialty & Generic median
Market cap 44.98m 24.65m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack